Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature
ConclusionsAcquired t(11;14)(q13;q32) is unreported in the multiple myeloma literature. In the era of targeted therapy, it is essential to repeat the cytogenetic and multiple myeloma fluorescencein situ hybridization panel with each disease progression. Multiple myeloma remains a challenging hematological malignancy despite advances in personalized/precision medicine.
Source: Journal of Medical Case Reports - Category: General Medicine Source Type: research
More News: Cancer & Oncology | Chemotherapy | Dexamethasone | General Medicine | Hematology | Leukemia | Lymphoma | Middle East Health | Myeloma | Revlimid | Saudi Arabia Health | Stem Cell Therapy | Stem Cells | Transplants | Velcade